FDA Approves Antidepressant With Fewer Sexual Side Effects

The Food and Drug Administration has approved Viibryd, a ground-breaking drug used to treat major depression.

The key advantage of the medication is its very limited sexual side effects, which are common under competing anti-depression drugs such as Zoloft and Prozac.

The most frequent side effects for Viibryd in the latest round of testing were nausea, diarrhea, insomnia and vomiting. As with other antidepressants, Viibryd will have a “black box” label — the FDA’s highest alert — that the drug during initial treatment carries an increased risk of suicidal thinking and behavior in children and young adults up to age 24.

“Major depressive disorder is disabling and prevents a person from functioning normally,” Dr. Thomas Laughren, the director of the psychiatry products division in the FDA’s Center for Drug Evaluation and Research, said in a news release. “Medications affect everyone differently, so it is important to have a variety of treatment options available to patients who suffer from depression.”

Clinical Data, Inc., the drug’s manufacturer,  said it expects Viibryd to be on pharmacy shelves within a few months.

Major depression is among the most common mental disorders in the United States, and frequently causes significant changes to appetite, energy level and sleeping habits.

Print Print  

Like what we're doing? We'd appreciate your support.

One comment to “FDA Approves Antidepressant With Fewer Sexual Side Effects”

  1. Susan Obirek

    When will it be available in Canada?

Leave a comment